hepatitis b-related hepatocellular carcinoma in stage II
Conditions
Interventions
Sponsors
the First Affiliated Hospital of Henan University of TCM
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. patients who meet the above criteria for diagnosis of HBV-related hepatocellular carcinoma; 2. clinical stage II of primary hepatocellular carcinoma; 3. administrated with comprehensive minimally invasive treatment witin 2 months. Images confirmed that there were no active lesions (up to CR) or measurable active lesions in vivo, which decreased by more than 80% compared with the original lesions (i.e., those with partial residual activity after comprehensive treatment, but could not be treated with minimally invasive treatment because of their special location). Child-Pugh grading A/B of liver function; 4. aged 18-75 years old male and female; 5. good general condition, Karnofsy score 60 within 1 week before enrollment; 6. syndrome differentiation in traditional Chinese medicine is the syndrome of deficiency and stasis; 7. the patient signed an informed consent to participate in the experimental study and was guaranteed to be followed up.
Exclusion criteria
Exclusion criteria: 1. In the past (within 5 years) or with other incurable malignant tumors at the same time; 2. aminotransferase (AST or ALT) > 5 times normal value and/or total bilirubin significantly increased > 3 times normal value; 3. patients with severe infection, fever, hemorrhagic tendency, refractory peritoneal effusion and stage III, IV hepatic encephalopathy; 4. severe heart, lung and kidney diseases, cerebral hemorrhage. Patients with accidental or severe diabetic complications; 5. pregnant or lactating women; patients with mental disorders; 6. allergic constitutions or known allergies to the components of the drug; 7. those who are participating in clinical trials of other drugs or receiving treatment with other traditional Chinese medicines; 8. Researchers believe that other causes are not suitable for clinical trials (e.g., combined with active alcoholic cirrhosis or autoimmune liver disease).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Alpha fetoprotein;HBV-DNA; | — |
Countries
China
Contacts
Public ContactMa Suping
the First Affiliated Hospital of Henan University of TCM
Outcome results
None listed